Invivogen

Kayla Therapeutics

Centre National De La Recherche Scientifique

Cayla

Gerard Tiraby

Daniel Drocourt

Fabienne Vernejoul

Thierry Lioux

Eric Perouzel

Gilles Etienne

Elise Armau

Arnaud Debin

Christophe Cazaux

Michèle Tiraby

Jean Paul Reynes

Jean-Paul Reynes

A cyclic dinucleotide compound of Formula (I): wherein Xis H or F; Xis H or F; at least one among Xand Xis a fluorine atom; Z is OH, OR, SH or SR, wherein: Ris Na or NH, or Ris an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; Band Bare bases chosen from Adenine, Hypoxanthine or Guanine, and Bis a different base than Band a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.

Cyclic dinucleotides for cytokine induction

A conjugated compound of formula Q-Z&#x2014;Rwherein Q is a TLR7 and/or TLR8 agonist and Z&#x2014;Ris a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

Conjugated TLR7 and/or TLR8 and TLR2 agonists

A conjugated compound of formula Q-Z&#x2014;Rwherein Q is a TLR7 and/or TLR8 agonist and Z&#x2014;Ris a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the conjugated compound and a polyanionic molecule and a pharmaceutical composition containing the conjugated compound or complex. Also described is the use of the conjugated compound or complex in the treatment of infection, cancer or immune disorders or for use in vaccines.

Compositions of TLR7 and/or TLR8 agonists conjugated to lipids

A conjugated compound of Formula I: Q-Z&#x2014;Rwherein Q is a TLR7 and/or TLR8 agonist and Z&#x2014;Ris a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II: 

Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists

The invention relates to a new series of bacterial plasmid vectors which are fully devoid of CpG and which can express synthetic genes which do not contain CpG in the bacteria

Synthetic genes and bacterial plasmids devoid of CpG

The present invention relates to two groups of suicide hybrid genes in which genes from one group specifically activate the pyrimidine nucleobase analog 5-fluorocytosine and genes from the other group activate the pyrimidine nucleoside analog azidothymidine to derivatives toxic for mammalian cells.The present invention further relates to methods for the selective killing of transfected tumor cells or immune cells using a single suicide hybrid gene or the combination of two suicide hybrid genes selected for a complementarity in their antimetabolic action. The present invention also relates to eukaryotic vectors comprising two expression suicide gene units, the first permitting the sensitization of tumor cells to 5-fluorocytosine and the second permitting the sensitization of HIV-infected cells to Azidothymidine in a synergistic fashion.

Suicide genes and new associations of pyrimidine nucleobase and

A method of transforming eukaryotic or prokaryotic hosts sensitive to an antibiotic of the phleomycin family to confer resistance to the antibiotic is disclosed in which a phleomycin resistance gene is used as a selectable marker.

Growing community of inventors

Toulouse, France

Gerard Tiraby